Skip to content
OpenCapital
Get started

Biohaven BHVN Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

ADMA Biologics logo
ADMA BiologicsADMA
$39.38M—
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$117.2M-34.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
——

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's common stock shares outstanding?
Biohaven (BHVN) reported common stock shares outstanding of $10.9M in Q1 2026.
How has Biohaven's common stock shares outstanding changed year-over-year?
Biohaven's common stock shares outstanding decreased by 92.0% year-over-year, from $136.82M to $10.9M.
What does common stock shares outstanding mean?
This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.